RecruitingNCT06943573
Psilocybin-assisted therapy for bipolar II depression
About this title
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
Read the official source — NCT06943573This study assesses depression symptoms.
Medication studyAges 19–65CanadaBipolarity
Understand this study
What is this study about?
This study assesses depression symptoms.
Who could participate?
This study is for people with type II bipolarity. Listed age limits: 19 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
This 12-week study includes up to 30 days of screening and compares a single 25 mg psilocybin-assisted therapy dose with a 1 mg active-placebo (an inactive comparison treatment) dose. The registry does not specify the number or timing of therapy sessions in the fields reviewed.
- Listed locations
- Vancouver and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Participation duration
- The study lasts 12 weeks, with up to 30 days for screening; one study dose is listed.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 15, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 90
- Sponsor
- Lakshmi N Yatham
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT06943573
- Official title
Show the full official title
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Vancouver · Ottawa · Toronto
Interested in joining this study?
Questions about this study
What is this study about?
This study assesses depression symptoms.
Who is behind this study?
The study sponsor is Lakshmi N Yatham.
Does this study involve medication?
Yes. The study involves medication, including psilocybin (25 mg) and psilocybin 1mg micro-dose.
Who can participate?
This study is for people with type II bipolarity. Listed age limits: 19 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
